The impact of galantamine on cognition and mood during electroconvulsive therapy: A pilot study.

The impact of galantamine on cognition and mood during electroconvulsive therapy: A pilot study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The impact of galantamine on cognition and mood during electroconvulsive therapy: A pilot study. Abstract Text:

John D Matthews,Mark Blais,Lawrence Park,Charles Welch,Matthew Baity,Jessica Murakami,Katherine Sklarsky,Caitlin Homberger,Maurizio Fava,

OBJECTIVES: The purpose of this study was to: (1) assess the effectiveness of galantamine in the prevention of cognitive impairments during ECT treatment and (2) to explore the safety and tolerability of galantamine during ECT treatment. METHODS: Nine consecutive ECT patients were given galantamine 4mg bid throughout the course of their ECT treatments followed by a second cohort of eight consecutive ECT patients who did not receive galantamine. Objective measures of cognitive functioning and depression severity were performed pre-ECT and post-ECT. Subjective ratings of depression, confusion, and side effects were obtained weekly. RESULTS: The two groups were similar in age, gender and admission Global Assessment Functioning (GAF) scores. There were no significant between group differences found with regards to mean seizure duration, energy administered to induce seizures, blood pressure, or heart rate during and post-ECT treatment. None of the patients discontinued galantamine due to side effects and there were no severe adverse drug reactions. Patients receiving galantamine performed significantly better on delayed memory and abstract reasoning following ECT. The galantamine group showed a greater but non-significant mood improvement (repeated measure ANOVA). CONCLUSIONS: Our data support the hypothesis that galantamine may reduce cognitive impairment during ECT, especially with regards to new learning. In addition, galantamine may also enhance the antidepressant action of ECT. Galantamine was both safe and well tolerated during ECT.

The impact of galantamine on cognition and mood during electroconvulsive therapy: A pilot study. Publishing Authors By Initials

JD Matthews,M Blais,L Park,C Welch,M Baity,J Murakami,K Sklarsky,C Homberger,M Fava,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The impact of galantamine on cognition and mood during electroconvulsive therapy: A pilot study. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of psychiatric research

VOLUME: 42

Page Numbers: 526-31

Journal Abbreviation:

ISSN: 0022-3956

DAY: 3

MONTH: 08

YEAR: 2007

The impact of galantamine on cognition and mood during electroconvulsive therapy: A pilot study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 376331

The impact of galantamine on cognition and mood during electroconvulsive therapy: A pilot study. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: The impact of galantamine on cognition and mood during electroconvulsive therapy: A pilot study. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The impact of galantamine on cognition and mood during electroconvulsive therapy: A pilot study.

AFFILIATION: Massachusetts General Hospital, Inpatient Psychiatric Services, 55 Fruit Street, Warren 1220, Boston, MA 02114, United States.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Psychiatr Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The impact of galantamine on cognition and mood during electroconvulsive therapy: A pilot study Related Publications

• A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
• Acupuncture for major depressive disorder: has its efficacy been disproved?
• Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
• Adaptation of dialectical behavior therapy skills training group for treatment-resistant depression.
• Antidepressant dose reduction and the risk of relapse in major depressive disorder.
• Augmenting antidepressants with folate: a clinical perspective.
• Bond strength of adhesive systems to human tooth enamel.
• Cat posture on a tilted platform.
• Comparison of quality of life measures in a depressed population.
• Delayed bezafibrate-induced angio-oedema in a 68-year-old man.
• Differential Antidepressant Symptom Efficacy: Placebo-Controlled Comparisons of Duloxetine and SSRIs (Fluoxetine, Paroxetine, Escitalopram).
• Financial conflicts of interest in psychiatry.
• Low-Income HIV-Infected Women and the Process of Engaging in Healthy Behavior.
• Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis.
• Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D study.
• Major depressive disorder with anger attacks and cardiovascular risk factors.
• Major depressive disorder with anger attacks and subcortical MRI white matter hyperintensities.
• Pain in depression: STAR*D study findings.
• Perceived stress and cognitive vulnerability mediate the effects of personality disorder comorbidity on treatment outcome in major depressive disorder: a path analysis study.
• Preadult onset vs. adult onset of major depressive disorder: a replication study.
• Psychosocial impairment in patients treated for pituitary disease: a controlled study.
• Recognizing and engaging depressed Chinese Americans in treatment in a primary care setting.
• Rehabilitation in endocrine patients: a novel psychosomatic approach.
• SUNCT and high nocturnal prolactin levels: some new unusual characteristics.
• Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine.
• The STAR*D study: treating depression in the real world.
• The utility of non-proportional quota sampling for recruiting at-risk women for microbicide research.
• Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder.
• Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes.
• Validation of the Patient Health Questionnaire-9 for depression screening among Chinese Americans.